6-8
Oct
2026
CPHI Milan 2026
Fiera Milano, Italy
12M49
Book a meeting

DIATHEVA

About DIATHEVA

Diatheva, an Italian biotech company and part of SOL Group (in 30+ countries with 7,000+ employees), specializes in CDMO services and customized assays. With a team of 20 highly skilled professionals (70% PhDs) managing R&D to production, Diatheva operates in two core areas:
-Biotech CDMO: offering agile, cost-effective end-to-end R&D and cGMP manufacturing of small clinical batches (antibodies, recombinant proteins, enzymes) and aseptic sterile fill & finish. -Molecular & Immunoenzymatic Assays: designing and manufacturing high-quality IVD, veterinary, food safety, and environmental PCR and ELISA kits. 

Read more Show less
Certifications
  • CE
    CE
  • GMP
    GMP
  • ISO
    ISO
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less

Meet us at

  • CPHI Milan 2026

    CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
  • Country/Region:
    Italy
  • Founded:
    2002
  • On CPHI since:
    2019
  • Certificates:
    3
  • Employees:
    1 - 24
Company types
Biopharmaceutical company
CMO/CDMO
Contract Service
Manufacturer/Innovator
Primary activities
Animal Health
API Producer
Biopharmaceutical
Contract Manufacturer
Generic APIs producer
Contact info
Show contact info Hide contact info

DIATHEVA Resources (2)

  • Custom Antibody Services

    Brochure Custom Antibody Services

    Diatheva can provide customized services for polyclonal and monoclonal antibodies for your specific application.


    A full service is available for all types of antibodies production, including antigen design, immunogen preparation, antibody development, antibody purification and characterization.


    Leverage our expertise in antibody production.

  • Contract Development and GMP Manufacturing Services

    Brochure Contract Development and GMP Manufacturing Services

    We are well positioned to efficiently and expertly support your entire project at all stages of biopharmaceutical development, from cell line generation through process development. 

    In our state-of-the art GMP production facility authorized by EMA we produce and release biological Active Pharmaceutical Ingredients (APIs) for preclinical and Phase I/II clinical trials.